2023
Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitus
2022
Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States
Bloch E, Zhu X, Krause P, Patel E, Grabowski M, Goel R, Auwaerter P, Tobian A. Comparing the Epidemiology and Health Burden of Lyme Disease and Babesiosis Hospitalizations in the United States. Open Forum Infectious Diseases 2022, 9: ofac597. PMID: 36467296, PMCID: PMC9709699, DOI: 10.1093/ofid/ofac597.Peer-Reviewed Original ResearchNational Inpatient SampleLyme diseaseMale patientsAnnual incidenceHealth burdenLonger hospital stayMean hospital chargesHigher inpatient costsHospital-level variablesStratified systematic random sampleUS Census Bureau dataPerson/yearHospital stayPatient demographicsHospital admissionClinical outcomesHospital chargesInpatient costsInpatient hospitalizationInpatient SampleAdmission costsHospitalizationUS hospitalsDisease severitySystematic random sample
2020
105 Babesiosis
Vannier E, Krause P. 105 Babesiosis. 2020, 799-802. DOI: 10.1016/b978-0-323-55512-8.00105-8.Peer-Reviewed Original ResearchPolymerase chain reactionProphylactic antibiotic regimenLife-threatening complicationsMainstay of treatmentSolid organ transplantationBest preventive measureAntibiotic regimenFrequent symptomsHospital admissionDefinitive diagnosisSevere babesiosisBlood productsOrgan transplantationEtiologic agentBabesia microtiPreventive measuresZoonotic diseaseChain reactionB. duncaniBabesiosisDiseaseB. venatorumHemoprotozoan parasitesB. divergensAlternative option
2003
Successful Treatment of Human Granulocytic Ehrlichiosis in Children Using Rifampin
Krause PJ, Corrow CL, Bakken JS. Successful Treatment of Human Granulocytic Ehrlichiosis in Children Using Rifampin. Pediatrics 2003, 112: e252-e253. PMID: 12949322, DOI: 10.1542/peds.112.3.e252.Peer-Reviewed Original ResearchConceptsHuman granulocytic ehrlichiosisYears of ageSuccessful treatmentGranulocytic ehrlichiosisTick-borne infectious diseaseFlu-like illnessTreatment of choiceHospital admissionClinical featuresSerious infectionsInfectious diseasesPhagocytophilum infectionRifampinAnaplasma phagocytophilumPermanent stainingChildrenInfectionTreatmentEhrlichiosisAgeYearsAdmissionIllnessDiseaseDoxycycline
2002
Babesiosis
Krause PJ. Babesiosis. Medical Clinics Of North America 2002, 86: 361-373. PMID: 11982307, DOI: 10.1016/s0025-7125(03)00092-0.Peer-Reviewed Original ResearchConceptsAge 50 yearsFlulike illnessThin blood smearsHIV infectionHospital admissionExchange transfusionAsplenic individualsImmunosuppressive drugsPolymerase chain reactionSevere casesSpecific diagnosisFatal diseaseBlood smearsProtozoal parasitesGreater riskLyme diseaseSpecific antibodiesChain reactionTransmits Lyme diseaseInfectionDiseaseBabesiosisSame tickNorthern midwestern United StatesMost cases